Jefferies analyst Eun Yang downgraded Biomea Fusion to Hold from Buy.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BMEA:
- Jefferies Reconsiders, BMEA Plummets after Sour Diabetes Drug Data
- Biomea Soars on Promising Phase 2 Data in Type 2 Diabetes
- Biomea Fusion price target raised to $45 from $40 at Piper Sandler
- 3 Best Stocks to Buy Now, 6/26/2023, According to Top Analysts
- JPMorgan ups Biomea Fusion target, adds to Analyst Focus List